% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@PHDTHESIS{Jackson:278574,
author = {Jackson, Joshua},
title = {{I}dentification of compensatory mechanisms and disease
pathways in mitochondrial disease and synucleinopathy},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
type = {Dissertation},
reportid = {DZNE-2025-00607},
pages = {97 p.},
year = {2025},
note = {Dissertation, Rheinische Friedrich-Wilhelms-Universität
Bonn, 2025},
abstract = {Mitochondria play vital roles in a variety of processes
such as cellular metabolism, intracellular signalling and
cell death. Defects in mitochondria can lead to inherited
metabolic disorders and neurodegenerative diseases. There is
often a poor genotype-to-phenotype correlation in
mitochondrial diseases, with distinct mutations that lead to
a wide variety of clinical manifestations, age of onset and
disease severity. This heterogeneity of symptoms, in
combination with a relatively low frequency in the
population, makes the development of novel treatments
particularly challenging.In invertebrates and some mouse
models of mitochondrial diseases, inhibition of the
mitochondrial oxidative phosphorylation (OXPHOS) can lead to
a paradoxical lifespan extension through the engagement of
compensatory mechanisms. As an explanation of this
phenomena, the “mitochondrial threshold effect theory”
states that mitochondrial dysfunction below a certain
threshold promotes stress resilience and metabolic rewiring,
leading to enhanced longevity. However, if damage exceeds a
certain threshold, animals develop disease. In a human
context, a better understanding of the “mitochondrial
threshold effect” may explain some of the molecular
signatures and variable disease traits observed in patients.
We sought to explore the compensatory mechanisms that
organisms activate in response to the inhibition of OXPHOS
using Caenorhabditis elegans as a genetically tractable
model, in combination with mouse and human cells. Our goals
were to investigate the underlying molecular mechanisms that
contribute to mitochondrial dysfunction and
neurodegenerative processes.By performing a cross-species
analysis, we identified VPS-39/VPS39 and SPL-1/SGPL1 to be
part of the molecular mechanisms that compensate for
mitochondrial dysfunction. In the context of
neurodegenerative processes, we found that the actin
nucleation promoting factor WSP-1/N-WASP is a disease
modifier that contributes to mitochondrial dysfunction and
proteotoxicity. Together, these results build on our growing
understanding of the mechanisms that counteract
mitochondrial dysfunction and pathogenic processes.},
cin = {AG Bano},
cid = {I:(DE-2719)1013003},
pnm = {351 - Brain Function (POF4-351)},
pid = {G:(DE-HGF)POF4-351},
typ = {PUB:(DE-HGF)11},
urn = {urn:nbn:de:hbz:5-82889},
url = {https://pub.dzne.de/record/278574},
}